XLRN News and Press, Acceleron Pharma Inc.

CyrusOne (CONE) and CoreSite (COR) agreed to be acquired in deals valued at $15 billion and $10 billion, respectively. Data centers have been a significant area of growth over the last couple of decades. Ranked by colocation and data center revenues, CyrusOne and CoreSite are the ...

Avoro Capital Advisors, a significant shareholder of Acceleron Pharma (XLRN +3.3%), has reiterated its opposition to the buyout offer made by Merck (MRK -1.2%). The third biggest shareholder of Acceleron (NASDAQ:XLRN) argues that the transaction “is ill-timed, undervalues the Company, ...

Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Ready to Hel...

Merck (NYSE:MRK) said that the HSR waiting period for its planned purchase of Acceleron Pharma (NASDAQ:XLRN) has expired.  Acceleron rose 3.2% in premarket trading. Merck is extending its tender offer for Acceleron (XLRN) until Nov. 18, according to a statement. Merck (MRK) lat...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Before the COVID-19 pandemic, Merck (NYSE: MRK ) stock was a good one to own. The performance of Merck stock matched that of the S&P 500 , and it paid a steadily rising dividend. Source: Atmosphere1 / Shutters...

McAfee to be acquired by an investor group comprised of Advent, Permira, Crosspoint Capital, CPP Investments, GIC, and ADIA for $14 billion. On November 5, 2021, Bloomberg reported that McAfee was in advanced talks to go private. CorePoint Lodging to be acquired by Highg...

In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. However, the big drugmaker recently revealed that it withdrew a key regulatory filing document related to the transaction. In this Motley Fool Live video ...

Believes Now Is the Wrong Time to Cash out of Acceleron, Given Company’s Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Sees Continuing as Standalone Entity as Clearly Superior Path for Acceleron Highlights What It Believes Was a Flawed ...

Acceleron Pharma (NASDAQ:XLRN): Q3 Non-GAAP EPS of -$0.95 beats by $0.06; GAAP EPS of -$1.16 misses by $0.18. Revenue of $34.2M (+51.3% Y/Y) misses by $1.19M. Press Release For further details see: Acceleron Pharma EPS beats by $0.06, misses on revenue

- Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL ® (luspatercept-aamt) - - Three clinical abstracts on REBLOZYL have been accepted for presentation at the 63rd American Society o...